Target intelligence / Profile preview

Ribonuclease pancreatic (RNASE1) (RNASE1)

Target
RNASE1
Molecular classification
Enzyme, Endonuclease, Secretory protein, Ligand
01

Overview

Ribonuclease pancreatic (RNASE1) is a potent secretory enzyme belonging to the Ribonuclease A superfamily that plays a critical role in regulating extracellular RNA levels. Its primary physiological function is the catalytic degradation of single- and double-stranded RNA in the extracellular space, which helps maintain vascular homeostasis by clearing pro-inflammatory and pro-coagulatory extracellular RNA (eRNA) released during cell death. Beyond its nuclease activity, RNASE1 has recently been identified as a non-canonical ligand for several receptor tyrosine kinases, including ALK in non-small cell lung cancer and EphA4 in breast cancer, where it triggers oncogenic signaling pathways independently of its catalytic function. In the tumor microenvironment, RNASE1 also contributes to immune evasion by internalizing into T cells and interacting with STAT1 to induce cellular dysfunction. Therapeutically, RNASE1 is being investigated both as a treatment (recombinant versions for cardiovascular and inflammatory diseases) and as a target (using inhibitors or antibodies to block its role in cancer progression).

Other names
HP-RNaseRIB-1RNase UpI-1Ribonuclease 1Ribonuclease ARAC1RNS1Ribonuclease A family member 1
02

Mechanism of action

Ligand-mediated activation of receptor tyrosine kinases (ALK, EphA4); Catalytic degradation of extracellular RNA; Inhibition of STAT1-mediated T-cell cytotoxicity

03

Biological functions

RNA degradationVascular homeostasisImmune response modulationSignal transductionExtracellular RNA clearanceDefense response to bacteria and viruses
04

Disease associations

CancerInflammationCardiovascular diseaseSepsisSystemic lupus erythematosusIschemia-reperfusion injury
05

Safety considerations

High affinity for endogenous ribonuclease inhibitor (RNH1) limiting therapeutic efficacyPotential for non-specific systemic RNA degradationImmunogenicity of engineered non-human or modified variants
06

Interacting drugs

Crizotinib

3 more in the full profile.

07

Biomarkers

Serum RNASE1 levelsRNASE1-driven ALK-activation (RDAA) statusRNASE1 glycosylation patternsExtracellular RNA (eRNA) levels

Beyond the preview

Go deeper on Ribonuclease pancreatic (RNASE1) (RNASE1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ribonuclease pancreatic (RNASE1) (RNASE1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call